<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma - Hartmann, T - 2015 | Cochrane Library</title> <meta content="Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma - Hartmann, T - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010615.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma - Hartmann, T - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010615.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010615.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma" name="citation_title"/> <meta content="Tim Hartmann" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Kai Hübel" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Ina Monsef" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Andreas Engert" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Nicole Skoetz" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="nicole.skoetz@uk-koeln.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD010615.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/10/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010615.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010615.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010615.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Benzylamines; Cyclams; Early Termination of Clinical Trials; Granulocyte Colony-Stimulating Factor [*pharmacology]; Hematopoietic Stem Cell Mobilization [*methods]; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds [*pharmacology]; Lymphoma [therapy]; Lymphoma, Non-Hodgkin [mortality, *therapy]; Multiple Myeloma [mortality, *therapy]; Randomized Controlled Trials as Topic; Time Factors; Transplantation, Autologous" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010615.pub2&amp;doi=10.1002/14651858.CD010615.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="bzu3XIhG";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010615\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010615\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010615.pub2",title:"Additional plerixafor to granulocyte colony\\u2010stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma",firstPublishedDate:"Oct 20, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematological Malignancies Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010615.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010615.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010615.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010615.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010615.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010615.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010615.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010615.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010615.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010615.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1735 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010615.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full#CD010615-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full#CD010615-sec-0086"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full#CD010615-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full#CD010615-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full#CD010615-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full#CD010615-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full#CD010615-sec-0051"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full#CD010615-sec-0080"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/appendices#CD010615-sec-0091"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/table_n/CD010615StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/table_n/CD010615StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/information#CD010615-cr-0002">Tim Hartmann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/information#CD010615-cr-0003">Kai Hübel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/information#CD010615-cr-0004">Ina Monsef</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/information#CD010615-cr-0005">Andreas Engert</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010615.pub2/information#CD010615-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Nicole Skoetz</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/information/en#CD010615-sec-0095">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 October 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010615.pub2">https://doi.org/10.1002/14651858.CD010615.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010615-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010615-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010615-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010615-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010615-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010615-abs-0001" lang="en"> <section id="CD010615-sec-0001"> <h3 class="title" id="CD010615-sec-0001">Background</h3> <p>Autologous stem cell transplantation is widely used to restore functioning bone marrow in people with malignant lymphoma or multiple myeloma after myeloablative chemotherapy. Results of some clinical trials indicate that plerixafor in addition to granulocyte colony‐stimulating factors (G‐CSF) compared to G‐CSF only could lead to an increased mobilisation and release of CD34‐positive cells, facilitating effective apheresis. </p> </section> <section id="CD010615-sec-0002"> <h3 class="title" id="CD010615-sec-0002">Objectives</h3> <p>To evaluate the efficacy and safety of additional plerixafor to G‐CSF for haematopoietic stem cell mobilisation in people with malignant lymphoma or multiple myeloma. </p> </section> <section id="CD010615-sec-0003"> <h3 class="title" id="CD010615-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1990 to September 2015), as well as conference proceedings (American Society of Hematology; American Society of Clinical Oncology; European Hematology Association; American Society for Blood and Marrow Transplantation; European Group for Blood and Marrow Transplantation) for studies. Two review authors independently screened search results. </p> </section> <section id="CD010615-sec-0004"> <h3 class="title" id="CD010615-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing plerixafor in addition to G‐CSF compared to G‐CSF only for stem cell mobilisation in people with malignant lymphoma or multiple myeloma of all stages and ages. We included full text as well as abstracts and unpublished data if sufficient information on study design, participant characteristics, interventions, and outcomes was available. We excluded cross‐over trials, quasi‐randomised trials, and post‐hoc retrospective trials. </p> </section> <section id="CD010615-sec-0005"> <h3 class="title" id="CD010615-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the results of the search strategies, extracted data, assessed quality, and analysed data according to standard Cochrane methods. We performed final interpretation with an experienced clinician. </p> </section> <section id="CD010615-sec-0006"> <h3 class="title" id="CD010615-sec-0006">Main results</h3> <p>We identified four RCTs fitting the inclusion criteria. However, two of these closed prematurely due to low recruitment and did not report results. The remaining two trials evaluated 600 participants with multiple myeloma or non‐Hodgkin lymphoma. In both studies the experimental group received G‐CSF plus plerixafor and the control group received G‐CSF plus placebo. </p> <p>The meta‐analysis showed no evidence for differences between plerixafor and placebo group regarding mortality at 12 months (600 participants; risk ratio (RR) 1.00, 95% confidence interval (CI) 0.59 to 1.69; P = 1.00; moderate‐quality evidence) and adverse events during stem cell mobilisation and collection (593 participants; RR 1.02, 95% CI 0.99 to 1.06; P = 0.19; high‐quality evidence). </p> <p>Regarding the outcome successful stem cell collection, the meta‐analysis showed an advantage for those participants randomised to the plerixafor group (600 participants; RR 2.42, 95% CI 1.98 to 2.96; P &lt; 0.00001; high‐quality evidence). </p> <p>As there was high heterogeneity between studies for the number of transplanted participants, we did not meta‐analyse these data. In the multiple myeloma study, 95.9% (142 participants) in the plerixafor arm and 88.3% (136 participants) in the placebo arm underwent transplantation (RR 1.09, 95% CI 1.02 to 1.16); in the non‐Hodgkin lymphoma trial, 90% (135 participants) in the plerixafor group versus 55.4% (82 participants) in the placebo group could be transplanted (RR 1.62, 95% CI 1.39 to 1.89). In both trials there was no evidence for a difference between participants in the plerixafor and placebo group in terms of time to neutrophil and platelet engraftment in transplanted participants. </p> <p>None of the trials reported on the outcomes quality of life and progression‐free survival.</p> </section> <section id="CD010615-sec-0007"> <h3 class="title" id="CD010615-sec-0007">Authors' conclusions</h3> <p>The results of the analysed data suggest that additional plerixafor leads to increased stem cell collection in a shorter time. There was insufficient evidence to determine whether additional plerixafor affects survival or adverse events. </p> <p>The two trials included in the meta‐analysis, both of which were conducted by the Genzyme Corporation, the manufacturer of plerixafor, were published several times. Two more RCTs examining the addition of plerixafor to a G‐CSF mobilisation regimen terminated early without publishing any outcome. The trials included nine and five participants, respectively. Another RCT with 100 participants was recently completed, but has not yet published outcomes. Due to the unpublished RCTs, it is possible that our review is affected by publication bias, even though two trials failed to recruit a sufficient number of participants to analyse any data. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010615-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010615-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010615-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010615-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010615-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010615-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010615-abs-0004" lang="en"> <h3>Adding plerixafor to G‐CSF for stem cell mobilisation for autologous transplantation in people with certain cancers of the blood </h3> <p><b>Review question</b> </p> <p>We reviewed the existing literature regarding the efficacy and safety of additional plerixafor to granulocyte colony‐stimulating factors (G‐CSF) versus G‐CSF only for stem cell mobilisation in people with malignant lymphoma and multiple myeloma, cancers of the blood. </p> <p><b>Background</b> </p> <p>Malignant lymphoma can be differentiated into Hodgkin and non‐Hodgkin lymphoma, and usually affects the lymph nodes and the lymphatic system. Multiple myeloma is a cancer of the bone marrow. An effective treatment option for non‐Hodgkin lymphoma and multiple myeloma is high‐dose chemotherapy followed by autologous stem cell transplantation. In autologous transplantation, stem cells are collected from the patient's blood prior to high‐dose chemotherapy, which must be mobilised from the bone marrow in the blood. A commonly used agent for stem cell mobilisation is G‐CSF. Recent studies have suggested that the addition of the new agent plerixafor, which was originally developed for the treatment of HIV infection, to G‐CSF could lead to higher stem cell harvest and thereby increase the probability of successful transplantation after chemotherapy. </p> <p><b>Study characteristics</b> </p> <p>We searched several medical databases and identified four randomised controlled trials that met our inclusion criteria. Two of the four studies terminated early due to low recruitment (14 participants included) and did not release any results. We were therefore unable to include them in our statistical analysis. The two published analysed trials included 600 participants with multiple myeloma and non‐Hodgkin lymphoma. In both studies, the experimental group received G‐CSF plus plerixafor subcutaneously, and the control group received G‐CSF plus placebo. Both trials were sponsored by Genzyme, the manufacturer of plerixafor. </p> <p><b>Key results</b> </p> <p>We were able to conduct a meta‐analysis of the data of the two studies for the outcomes mortality at 12 months, successful stem cell collection, and adverse events. </p> <p>We found no evidence for a difference between the plerixafor and placebo group for the outcomes mortality at 12 months and adverse events during stem cell mobilisation period. </p> <p>The meta‐analysis showed an advantage for those participants randomised to plerixafor for the outcome successful stem cell collection. Furthermore, in both studies the time to collect a defined number of stem cells was significantly shorter in the plerixafor group compared to the placebo group. </p> <p>In the study that enrolled people with multiple myeloma, 95.9% of the participants in the plerixafor arm and 88.3% in the placebo arm underwent transplantation. In the study that examined people with non‐Hodgkin lymphoma, 90% of the participants in the plerixafor group and only 55.4% in the placebo group could be transplanted. It seems that especially people with non‐Hodgkin lymphoma benefit from the addition of plerixafor in terms of successful transplantation, but there was no evidence for a difference for time to neutrophil and platelet engraftment in transplanted participants. </p> <p>None of the trials reported on quality of life or progression‐free survival.</p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence was high for adverse events and successful stem cell collection and moderate for mortality at 12 months. The main limitation was a wide confidence interval. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010615-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010615-sec-0086"></div> <h3 class="title" id="CD010615-sec-0087">Implications for practice</h3> <section id="CD010615-sec-0087"> <p>The results of the analysed data suggest that additional plerixafor could lead to increased stem cell collection in a shorter time. There was insufficient evidence to determine whether additional plerixafor affects overall survival or adverse events. People with NHL might benefit from the addition of plerixafor to G‐CSF in terms of successful transplantation, but there was no evidence for a difference in this outcome for people with MM. </p> <p>The results of this review should be interpreted considering that two RCTs, <a href="./references#CD010615-bbs2-0004" title="NCT01301963. Filgrastim with or without plerixafor in treating patients with multiple myeloma previously treated with lenalidomide. https://clinicaltrials.gov/ct2/show/record/NCT01301963 (accessed 30 November 2014). ">NCT01301963</a> and <a href="./references#CD010615-bbs2-0003" title="NCT00665314. Evaluation of the safety and efficacy of the addition of AMD3100 to a G‐CSF mobilization regimen in patients with lymphoma (NHL and HD) and multiple myeloma (MM). https://clinicaltrials.gov/ct2/show/NCT00665314 (accessed 30 November 2014). ">NCT00665314</a>, were terminated early due to low recruitment (a total of 14 participants), without the publishing of any outcomes. In comparison, the meta‐analysed studies, <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a> and <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a>, conducted by the Genzyme Corporation, were published several times. A recently completed RCT will probably release results in the near future (<a href="./references#CD010615-bbs2-0011" title="NCT01767714. Evaluation of Plerixafor Plus G‐CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non‐Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation. https://www.clinicaltrials.gov/ct2/show/NCT01767714?term=NCT01767714&amp;rank=1 (accessed 30 May 2015). ">NCT01767714</a>). </p> </section> <h3 class="title" id="CD010615-sec-0088">Implications for research</h3> <section id="CD010615-sec-0088"> <p>For a better comparability of G‐CSF plus plerixafor and G‐CSF alone, all conducted RCTs must be published and further randomised studies with relevant outcomes like overall survival, engraftment, adverse events, quality of life, progression‐free survival, and successful stem‐cell collection should be performed. Regarding the outcome successful stem cell collection, future trials should define similar endpoints. In addition, the further development of a risk‐adapted, cost‐effective approach for the use of plerixafor could be a point of research in the future. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010615-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010615-sec-0022"></div> <div class="table" id="CD010615-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Plerixafor versus placebo for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Plerixafor versus placebo for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma<br/> <b>Settings:</b> Hospital<br/> <b>Intervention:</b> Plerixafor versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Plerixafor</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality (12 months)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1</b> <br/> (0.59 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>600<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>moderate <sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>As overall survival has not been reported, we calculated mortality at 12 months</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> <br/> (49 to 140) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to engraftment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported with standard error or standard deviation, therefore no meta‐analysis possible </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of transplanted participants</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to high heterogeneity we did not pool the data</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Successful stem cell collection</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>654 per 1000</b> </p> <p>(535 to 799)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.42</b> </p> <p>(1.98 to 2.96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (during stem cell mobilisation and collection)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.02</b> <br/> (0.99 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>593<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>939 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>958 per 1000</b> <br/> (930 to 996) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to imprecision: wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010615-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010615-sec-0023"></div> <section id="CD010615-sec-0024"> <h3 class="title" id="CD010615-sec-0024">Description of the condition</h3> <p>Malignant lymphomas are malignancies of the lymph nodes and lymphatic system with possible involvement of other organs, and can be differentiated into non‐Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). Multiple myeloma (MM) is a malignancy of the bone marrow and is classified among the plasma cell neoplasms by the World Health Organization (WHO). </p> <p>Non‐Hodgkin lymphoma derives from B and T lymphocytes or natural killer (NK) cells at varying stages of maturation. The most common classification of NHL is the WHO system, which was last updated in 2008. It classifies the NHL in B‐cell neoplasms and T/NK‐cell neoplasms, whereby about 85% of the NHL descends from mature and progenitor B lymphocytes (<a href="./references#CD010615-bbs2-0027" title="HeroldG . Innere Medizin. Herold G, 2013. ">Herold 2013</a>; <a href="./references#CD010615-bbs2-0033" title="JaffeES . The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009:523‐31. [PUBMED: 20008237] ">Jaffe 2009</a>). A clinical approach is the classification to indolent NHL (approximately 70% of all NHLs) and aggressive NHL (approximately 30% of all NHLs) (<a href="./references#CD010615-bbs2-0027" title="HeroldG . Innere Medizin. Herold G, 2013. ">Herold 2013</a>). The annual incidence of NHL varies between different regions in the world. In North America, the incidence is estimated to be 13.7 per 100,000 inhabitants, while in the European Union, it is 8.3 per 100,000 inhabitants, with the global incidence amounting to 5.1 per 100,000 inhabitants. The worldwide mortality is 2.5% and is quite similar in the various global regions (<a href="./references#CD010615-bbs2-0023" title="International Agency for Research on Cancer. Globocan 2008. http://globocan.iarc.fr (accessed 30 May 2015). ">GLOBOCAN 2008</a>). The median age at diagnosis is around 60 years, and varies only slightly between the diverse types of NHL (<a href="./references#CD010615-bbs2-0027" title="HeroldG . Innere Medizin. Herold G, 2013. ">Herold 2013</a>). </p> <p>Hodgkin lymphoma arises from germinal centre or post‐germinal centre B cells, and is associated with unique neoplastic cells called Reed‐Sternberg cells, which morphologically differentiate HL from NHL. The WHO classifies HL into two types: the classic (approximately 93% of all HLs) and the nodular lymphocyte predominant (approximately 7% of all HLs) (<a href="./references#CD010615-bbs2-0024" title="GobbiPG , FerreriAJ , PonzoniM , LevisA . Hodgkin lymphoma. Critical reviews in oncology/hematology2013;85(2):216‐37. [PUBMED: 22867814] ">Gobbi 2013</a>; <a href="./references#CD010615-bbs2-0027" title="HeroldG . Innere Medizin. Herold G, 2013. ">Herold 2013</a>). HL accounts for about 10% of all lymphomas and has an annual incidence of 2 to 3 per 100,000 inhabitants in Western countries (<a href="./references#CD010615-bbs2-0036" title="JemalA , SiegelR , WardE , HaoY , XuJ , ThunMJ . Cancer statistics, 2009. CA: A Cancer Journal for Clinicians2009;59(4):225‐49. ">Jemal 2009</a>; <a href="./references#CD010615-bbs2-0046" title="SantM , AllemaniC , TereanuC , DeAngelisR , CapocacciaR , VisserO , et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood2010;116(19):3724‐34. ">Sant 2010</a>; <a href="./references#CD010615-bbs2-0050" title="SmithA , HowellD , PatmoreR , JackA , RomanE . Incidence of haematological malignancy by sub‐type: a report from the Haematological Malignancy Research Network. British Journal of Cancer2011;105(11):1684‐92. ">Smith 2011</a>). Hence, HL is a comparatively rare disease, but it is one of the most common malignancies in young adults. In industrialised countries, the age distribution of HL shows a first peak in the third decade and a second peak around the age of 60 (<a href="./references#CD010615-bbs2-0027" title="HeroldG . Innere Medizin. Herold G, 2013. ">Herold 2013</a>). </p> <p>Multiple myeloma, one of the mature B‐cell neoplasms, is characterised by the accumulation of malignant plasma cells in the bone marrow compartment, the increased production of a monoclonal immunoglobulin, and bone destruction. MM may be preceded by a pre‐malignant state called monoclonal gammopathy of undetermined significance. Overall, MM accounts for approximately 10% of all haematologic malignancies and 1% of all cancers (<a href="./references#CD010615-bbs2-0049" title="SiegelR , NaishadhamD , JemalA . Cancer statistics. CA: A Cancer Journal for Clinicians2012;63(1):11‐30. ">Siegel 2012</a>). The annual incidence is approximately 4 to 5 per 100,000 inhabitants in Western countries (<a href="./references#CD010615-bbs2-0043" title="PhekooKJ , ScheySA , RichardsMA , BevanDH , BellS , GillettD , et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. British Journal of Haematology2004;127(3):299‐304. ">Phekoo 2004</a>; <a href="./references#CD010615-bbs2-0046" title="SantM , AllemaniC , TereanuC , DeAngelisR , CapocacciaR , VisserO , et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood2010;116(19):3724‐34. ">Sant 2010</a>; <a href="./references#CD010615-bbs2-0050" title="SmithA , HowellD , PatmoreR , JackA , RomanE . Incidence of haematological malignancy by sub‐type: a report from the Haematological Malignancy Research Network. British Journal of Cancer2011;105(11):1684‐92. ">Smith 2011</a>). MM is an adult‐onset disease, with a median age at diagnosis of 66 and only 2% of people younger than 40 years of age (<a href="./references#CD010615-bbs2-0037" title="KyleRA , GertzMA , WitzigTE , LustJA , LacyMQ , DispenzieriA , et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings2003;78(1):21‐33. ">Kyle 2003</a>). To date, no curative approach exists for MM, and depending on the therapy, the overall survival varies between a few months and some years. The 10‐year survival rate of young patients with ideal treatment is around 50% (<a href="./references#CD010615-bbs2-0027" title="HeroldG . Innere Medizin. Herold G, 2013. ">Herold 2013</a>). </p> </section> <section id="CD010615-sec-0025"> <h3 class="title" id="CD010615-sec-0025">Description of the intervention</h3> <p>High‐dose chemotherapy in combination with autologous stem cell transplantation is a widely used effective treatment option for people with NHL, HL, and MM (<a href="./references#CD010615-bbs2-0041" title="Naumann‐WinterF , GrebA , BorchmannP , BohliusJ , EngertA , SchnellR . First‐line tandem high‐dose chemotherapy and autologous stem cell transplantation versus single high‐dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD004626.pub3] ">Naumann‐Winter 2012</a>; <a href="./references#CD010615-bbs2-0044" title="RanceaM , MonsefI , vonTresckowB , EngertA , SkoetzN . High‐dose chemotherapy followed by autologous stem cell transplantation for patients with refractory/relapsed Hodgkin lymphoma. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD009411] ">Rancea 2013</a>; <a href="./references#CD010615-bbs2-0047" title="SchaafM , ReiserM , BorchmannP , EngertA , SkoetzN . High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular lymphoma in adults. Cochrane Database of Systematic Reviews2012, Issue 1. [DOI: 10.1002/14651858.CD007678.pub2] ">Schaaf 2012</a>). Stem cell transplantation is directed at restoring a functioning bone marrow in patients after myeloablative chemotherapy. In contrast to allogeneic transplantation with donor cells, in the autologous setting stem cells are collected from the patient and re‐infused after the high‐dose chemotherapy (<a href="./references#CD010615-bbs2-0035" title="JantunenE , SuredaA . The evolving role of stem cell transplants in lymphomas. Biology of Blood and Marrow Transplantation2012;18(5):660‐73. [PUBMED: 21963876] ">Jantunen 2012</a>). </p> <p>Commonly used agents for stem cell mobilisation are granulocyte colony‐stimulating factors (G‐CSF). The patient receives G‐CSF for up to eight days, and as soon as sufficient CD34‐positive cells are detectable in the patient's peripheral blood, the stem cells are collected by stem cell harvest (apheresis) and stored for transplantation after the myeloablative therapy (<a href="./references#CD010615-bbs2-0035" title="JantunenE , SuredaA . The evolving role of stem cell transplants in lymphomas. Biology of Blood and Marrow Transplantation2012;18(5):660‐73. [PUBMED: 21963876] ">Jantunen 2012</a>). The two types of traditional mobilisation methods, G‐CSF with chemotherapy (chemo‐mobilisation) or without chemotherapy ('steady‐state'), lead to a failure rate of 5% to 40% of the cases, depending on definition, disease, and mobilisation agents used (<a href="./references#CD010615-bbs2-0034" title="JantunenE , KvalheimG . Mobilization strategies in hard‐to‐mobilize patients with lymphoid malignancies. European Journal of Haematology2010;85:463‐71. ">Jantunen 2010</a>). In contrast to G‐CSF mobilisation alone, chemo‐mobilisation leads to higher stem cell yield, a higher probability of getting grafts with a large number of CD34+ cells, the need for fewer apheresis procedures, and even to an antitumour effect. But chemo‐mobilisation is associated with higher toxicity and increased probability of complications (<a href="./references#CD010615-bbs2-0016" title="BensingerW , DiPersioJF , McCartyJM . Improving stem cell mobilization strategies: future directions. Bone Marrow Transplantation2009;43:181‐95. ">Bensinger 2009</a>; <a href="./references#CD010615-bbs2-0021" title="GertzMA . Current status of stem cell mobilization. British Journal of Haematology2010;150:647‐62. ">Gertz 2010</a>). Major risk factors for mobilisation failure are advanced age, the diagnosis of NHL, progressive disease, previous radiotherapy, bone marrow involvement or prior treatment with lenalidomide or purine analogues, thrombocytopenia, and the failure of previous mobilisation attempts (<a href="./references#CD010615-bbs2-0015" title="BasakGW , JaksicO , KoristekZ , MikalaG , MayerJ , MassziT , et al. Identification of prognostic factors for plerixafor‐based hematopoietic stem cell mobilization. American Journal of Hematology2011;86:550‐3. ">Basak 2011</a>; <a href="./references#CD010615-bbs2-0039" title="MalardF , KrogerN , GabrielIH , HubelK , ApperleyJF , BasakGW , et al. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biology of Blood and Marrow Transplantation2012;18(2):314‐7. ">Malard 2011</a>). </p> <p>Plerixafor is a new agent that apparently improves mobilisation and stem cell harvest, thereby reducing the required number of apheresis procedures (<a href="./references#CD010615-bbs2-0034" title="JantunenE , KvalheimG . Mobilization strategies in hard‐to‐mobilize patients with lymphoid malignancies. European Journal of Haematology2010;85:463‐71. ">Jantunen 2010</a>). It has mainly been studied in combination with G‐CSF mobilisation. Before its approval in Europe, plerixafor was only available at transplant centres in the compassionate use program. Positive results of this programme evaluating plerixafor in combination with G‐CSF in patients who had previously failed a mobilisation attempt (60% to 75%) strongly indicate the efficacy of this agent (<a href="./references#CD010615-bbs2-0015" title="BasakGW , JaksicO , KoristekZ , MikalaG , MayerJ , MassziT , et al. Identification of prognostic factors for plerixafor‐based hematopoietic stem cell mobilization. American Journal of Hematology2011;86:550‐3. ">Basak 2011</a>; <a href="./references#CD010615-bbs2-0032" title="HubelK , FresenMM , SalwenderH , BasaraN , BeierR , TheurichS , et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplantation2011;46:1045‐52. ">Hubel 2011</a>). Based on promising data from phase II studies, randomised controlled trials (RCTs) were initiated comparing G‐CSF in combination with plerixafor to G‐CSF and placebo (<a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>; <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a>). </p> </section> <section id="CD010615-sec-0026"> <h3 class="title" id="CD010615-sec-0026">How the intervention might work</h3> <p>Plerixafor (formerly AMD3100) was originally developed for the treatment of HIV infection. It inhibits the CXCR4 chemokine receptor that blocks the receptor binding of the stromal cell–derived factor‐1α. This interaction leads to the mobilisation of haematopoietic stem cells from the bone marrow into the peripheral blood, in mice as well as in humans (<a href="./references#CD010615-bbs2-0017" title="BroxmeyerHE , OrschellCM , ClappDW , HangocG , CooperS , PlettPA , et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. The Journal of Experimental Medicine2005;201(8):1307‐18. [PUBMED: 15837815] ">Broxmeyer 2005</a>; <a href="./references#CD010615-bbs2-0026" title="HatseS , PrincenK , VermeireK , GerlachLO , RosenkildeMM , SchwartzTW , et al. Mutations at the CXCR4 interaction sites for AMD3100 influence anti‐CXCR4 antibody binding and HIV‐1 entry. FEBS Letters2003;546(2‐3):300‐6. [PUBMED: 12832058] ">Hatse 2003</a>; <a href="./references#CD010615-bbs2-0006" title="MaziarzRT , MicallefIN , StiffP , BolwellBJ , MarulkarS , CalandraGC , et al. Plerixafor plus G‐CSF is an effective regimen to mobilize hematopoietic stem cells in NHL patients with circulating peripheral blood CD34+ cells/{micro}l &lt; 10. Blood2009;114:33. MaziarzRT , NademaneeAP , MicallefIN , StiffPJ , CalandraG , AngellJ , et al. Plerixafor plus granulocyte colony‐stimulating factor improves the mobilization of hematopoietic stem cells in patients with non‐Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biology of Blood and Marrow Transplantation2013;19:670‐5. ">Maziarz 2013</a>). Moreover, plerixafor and G‐CSF are synergistic. Results of clinical trials indicate that plerixafor plus G‐CSF leads to an increased augmentation of mobilisation and release of CD34+ cells into the peripheral blood, facilitating effective apheresis (<a href="./references#CD010615-bbs2-0016" title="BensingerW , DiPersioJF , McCartyJM . Improving stem cell mobilization strategies: future directions. Bone Marrow Transplantation2009;43:181‐95. ">Bensinger 2009</a>). </p> </section> <section id="CD010615-sec-0027"> <h3 class="title" id="CD010615-sec-0027">Why it is important to do this review</h3> <p>Even though a Health Technology Assessment (HTA) report of the Ludwig Boltzmann Institute has already evaluated the role of plerixafor (<a href="./references#CD010615-bbs2-0031" title="HintringerK . Plerixafor (Mozobil ®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma, DSD: Horizon Scanning in Oncology. 1. Vol. 8, Vienna, Austria: Ludwig Boltzmann Gesellschaft GmbH, 2010. ">Hintringer 2010</a>), this systematic review will be of high relevance because a new systematic literature search will be performed and recent research results will be included. At the time of publication of the HTA report in March 2010, at least two clinical trials were still ongoing. No new systematic literature search was run for the HTA report, and it only evaluated the evidence used during the European approval process in the European Public Assessment Report of the European Medicines Agency, already published in 2009. </p> <p>Based on the published trials, plerixafor might be an effective mobilisation agent in the treatment of people with NHL, HL, and MM. A systematic review and meta‐analysis will provide the conclusive evidence to clarify the role of this agent and will also examine differences of treatment effectiveness caused by population group or chemotherapy agents. Evidence for the best therapeutic options is needed for decision‐making at both the level of the individual patient and the healthcare system. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010615-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010615-sec-0028"></div> <p>To evaluate the efficacy and safety of additional plerixafor to G‐CSF for haematopoietic stem cell mobilisation in people with malignant lymphoma or multiple myeloma. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010615-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010615-sec-0029"></div> <section id="CD010615-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010615-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included only RCTs. We excluded cross‐over trials and quasi‐randomised trials. We included full text as well as abstracts and unpublished data if sufficient information on study design, participant characteristics, interventions, and outcomes was available. </p> </section> <section id="CD010615-sec-0032"> <h4 class="title">Types of participants</h4> <p>We examined people with histologically confirmed diagnosis of NHL, HL, or MM requiring high‐dose chemotherapy followed by autologous stem cell transplantation, without age or gender restriction. We considered all stages and subtypes of malignant lymphoma or multiple myeloma, including people newly diagnosed, relapsed, or with resistant disease. </p> </section> <section id="CD010615-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We evaluated additional plerixafor compared to placebo or no additional therapy for stem cell mobilisation. </p> <p>Apart from the experimental/control intervention, participants in both groups had been intended to receive identical treatment for stem cell mobilisation (for example G‐CSF) and supportive care. </p> </section> <section id="CD010615-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD010615-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010615-list-0001"> <li> <p>Overall survival</p> </li> <li> <p>Successful stem cell collection</p> </li> </ol> </p> </section> <section id="CD010615-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010615-list-0002"> <li> <p>Progression‐free survival</p> </li> <li> <p>Proportion of participants achieving the optimal CD34+ cell target for transplantation</p> </li> <li> <p>Time to engraftment in transplanted participants</p> </li> <li> <p>Number of transplanted patients</p> </li> <li> <p>Quality of life, if measured with reliable and valid instruments</p> </li> <li> <p>Adverse events</p> </li> </ol> </p> </section> </section> </section> <section id="CD010615-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We used search strategies based on those described in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010615-bbs2-0038" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. ">Lefebvre 2011</a>)<i>.</i> We did not use any language constraints. </p> <section id="CD010615-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases:</p> <p> <ul id="CD010615-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library, September 2015) (see <a href="./appendices#CD010615-sec-0092">Appendix 1</a>) </p> </li> <li> <p>MEDLINE (1990 to September 2015, for search strategy see <a href="./appendices#CD010615-sec-0093">Appendix 2</a>) </p> </li> </ul> </p> </section> <section id="CD010615-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We searched conference proceedings of the following annual meetings that were not included in CENTRAL for abstracts: </p> <p> <ul id="CD010615-list-0004"> <li> <p>American Society of Hematology (2005 to 2014)</p> </li> <li> <p>American Society of Clinical Oncology (2005 to 2015)</p> </li> <li> <p>European Hematology Association (2005 to 2015)</p> </li> <li> <p>American Society for Blood and Marrow Transplantation (2005 to 2014)</p> </li> <li> <p>European Group for Blood and Marrow Transplantation (2005 to 2014)</p> </li> </ul> </p> <p>We electronically searched the metaRegister of Controlled Trials (<a href="http://www.isrctn.com/page/mrct" target="_blank">http://www.isrctn.com/page/mrct</a>) for ongoing trials. </p> <p>We handsearched the references of all identified trials, relevant review articles, and current treatment guidelines. </p> </section> </section> <section id="CD010615-sec-0040"> <h3 class="title" id="CD010615-sec-0040">Data collection and analysis</h3> <section id="CD010615-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (TH, NS) independently screened the results of the search strategies for eligibility by reading the abstracts. In cases of disagreement, we obtained the full‐text publication. If we could not reach consensus, we consulted a third review author, in accordance with Chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010615-bbs2-0028" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). </p> <p>We documented the study selection process in a flow chart as recommended in the PRISMA statement (<a href="./references#CD010615-bbs2-0040" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006‐12. [PUBMED: 19631508] ">Moher 2009</a>), showing the total numbers of retrieved references and the numbers of included and excluded studies. </p> </section> <section id="CD010615-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted the data according to the guidelines proposed by <a href="./references#CD010615-bbs2-0028" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. ">Higgins 2011</a>. Where required, we contacted authors of individual studies for additional information. We used a standardised data extraction form containing the following items: </p> <p> <ul id="CD010615-list-0005"> <li> <p>General information: author, title, source, publication date, country, language, duplicate publications. </p> </li> <li> <p>Quality assessment: sequence generation, allocation concealment, blinding (participants, personnel, outcome assessors), incomplete outcome data, selective outcome reporting, other potential sources of bias. </p> </li> <li> <p>Study characteristics: trial design, aims, setting and dates, source of participants, inclusion/exclusion criteria, comparability of groups, subgroup analysis, statistical methods, power calculations, treatment cross‐overs, compliance with assigned treatment, length of follow‐up, time point of randomisation. </p> </li> <li> <p>Participant characteristics: underlying disease, stage of disease, histological subtype, additional diagnoses, age, gender, ethnicity, number of participants recruited/allocated/evaluated, participants lost to follow‐up, type of treatment (multi‐agent chemotherapy (intensity of regimen, number of cycles), additional radiotherapy). </p> </li> <li> <p>Interventions: type, duration, and intensity of plerixafor.</p> </li> <li> <p>Outcomes: overall survival, progression‐free survival, proportion of participants achieving the optimal CD34+ cell target for transplantation, time to engraftment, quality of life, adverse events. </p> </li> </ul> </p> </section> <section id="CD010615-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (TH, NS) independently assessed the risk of bias for each study using the following criteria outlined in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010615-bbs2-0029" title="HigginsJPT , AltmanDG . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. ">Higgins 2011a</a>). </p> <p> <ul id="CD010615-list-0006"> <li> <p>Sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding (participants, personnel, outcome assessors)</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other potential sources of bias</p> </li> </ul> </p> <p>We made a judgement for every criterion, using one of three categories.</p> <p> <ol id="CD010615-list-0007"> <li> <p>'Low risk': if the criterion was adequately fulfilled in the study, i.e. the study was at a low risk of bias for the given criterion. </p> </li> <li> <p>'High risk': if the criterion was not fulfilled in the study, i.e. the study was at high risk of bias for the given criterion. </p> </li> <li> <p>'Unclear': if the study report provided insufficient information to allow for a judgement of 'Yes' or 'No', or if the risk of bias was unknown for the given criterion. </p> </li> </ol> </p> </section> <section id="CD010615-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We used intention‐to‐treat data. For binary outcomes, we calculated risk ratios with 95% confidence intervals for each trial. For time‐to‐event outcomes, we extracted hazard ratios from published data according to Parmar and Tierney (<a href="./references#CD010615-bbs2-0042" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. [PUBMED: 9921604] ">Parmar 1998</a>; <a href="./references#CD010615-bbs2-0052" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. [PUBMED: 17555582] ">Tierney 2007</a>). We calculated continuous outcomes as standardised mean differences. </p> </section> <section id="CD010615-sec-0045"> <h4 class="title">Dealing with missing data</h4> <p>As suggested in Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010615-bbs2-0030" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. ">Higgins 2011b</a>), we had to take into account many potential sources of missing data: at study level, at outcome level, and at summary data level. Firstly, it was important to distinguish between 'missing at random' and 'not missing at random'. We contacted the original investigators to request missing data. If we were unable to obtain missing data, we made explicit assumptions of any methods used, for example, that we assumed the data to be missing at random or that we assumed the missing values to have a particular value, such as a poor outcome. We imputed missing data for participants who were lost to follow‐up after randomisation (dichotomous data) assuming poor outcome ('worst‐case scenario') for missing participants. We performed sensitivity analysis to assess how sensitive results were to reasonable changes in the assumptions that we made. We addressed the potential impact of missing data on the findings of the review in the discussion. </p> </section> <section id="CD010615-sec-0046"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity of treatment effects between trials by using a Chi<sup>2</sup> test with a significance level at P less than 0.1. We used the I<sup>2</sup> statistic to quantify possible heterogeneity (I<sup>2</sup> greater than 30%, moderate heterogeneity; I<sup>2</sup> greater than 75%, considerable heterogeneity) (<a href="./references#CD010615-bbs2-0019" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. ">Deeks 2011</a>). We explored potential causes of heterogeneity by sensitivity and subgroup analyses. </p> </section> <section id="CD010615-sec-0047"> <h4 class="title">Assessment of reporting biases</h4> <p>In meta‐analyses with at least 10 trials included for one outcome, we would have explored potential publication bias by generating a funnel plot and statistically tested this by using a linear regression test (<a href="./references#CD010615-bbs2-0051" title="SterneJAC , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. ">Sterne 2011</a>). We would have considered a P value of less than 0.1 to be significant for this test. However, as we analysed two trials only, we did not generate a funnel plot. </p> </section> <section id="CD010615-sec-0048"> <h4 class="title">Data synthesis</h4> <p>Where we considered the data sufficiently similar to be combined, we pooled results by applying meta‐analyses using the fixed‐effect model, and used the random‐effects model as a sensitivity analysis. If the trials were clinically too heterogeneous to combine, we performed subgroup analyses only without calculating an overall estimate. We performed analyses according to the recommendations of The Cochrane Collaboration and used the Cochrane statistical package Review Manager 5 for analysis (<a href="./references#CD010615-bbs2-0019" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. ">Deeks 2011</a>; <a href="./references#CD010615-bbs2-0045" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">Review Manager (RevMan)</a>). </p> <p>We created a 'Summary of findings' table on absolute risks in each group with the help of <a href="./references#CD010615-bbs2-0025" title="McMaster University. GRADEpro. McMaster University, 2014. ">GRADEpro 2014</a> and used it to summarise the evidence of overall survival, quality of life, progression‐free survival, time to engraftment, and adverse effects. At variance with the protocol, we added the second primary outcome, 'successful stem cell collection', and 'number of transplanted participants' to the <a href="./full#CD010615-tbl-0001">summary of findings Table for the main comparison</a>, as both are clinically important outcomes for transplanted patients. For clinical interpretation, we calculated numbers needed to treat for an additional beneficial outcome and numbers needed to treat for an additional harmful outcome, with corresponding 95% confidence intervals. </p> </section> <section id="CD010615-sec-0049"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We considered performing subgroup analyses using the following characteristics:</p> <p> <ul id="CD010615-list-0008"> <li> <p>Age (&lt; 60 years, ≥ 60 years)</p> </li> <li> <p>Gender (male, female)</p> </li> <li> <p>Underlying disease (NHL, MM, HL)</p> </li> <li> <p>Therapy (first‐line, relapse therapy) of underlying disease</p> </li> <li> <p>Dosage of plerixafor</p> </li> <li> <p>Additional drugs for mobilisation (e.g. G‐CSF)</p> </li> </ul> </p> <p>However, as only two trials provided data, we did not perform these analyses.</p> </section> <section id="CD010615-sec-0050"> <h4 class="title">Sensitivity analysis</h4> <p>We considered performing sensitivity analyses using the following quality criteria:</p> <p> <ul id="CD010615-list-0009"> <li> <p>Quality components with regard to low and high risk of bias</p> </li> <li> <p>Fixed‐effect modelling versus random‐effects modelling</p> </li> </ul> </p> <p>Again, as only two trials provided data, we did not perform these analyses.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010615-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010615-sec-0051"></div> <section id="CD010615-sec-0052"> <h3 class="title">Description of studies</h3> <section id="CD010615-sec-0053"> <h4 class="title">Results of the search</h4> <p>The search strategies resulted in a total of 855 potentially relevant references. After screening the titles and abstracts of these publications, we excluded 829 references at initial stage. After evaluating the full‐text publications of the remaining 26 references, we excluded four studies (six references) that did not match our methodological demands and a further five studies that were still ongoing. Finally, we included 15 references of four trials that fulfilled the methods criteria. However, only two of these trials provided data and were included in the meta‐analysis. One trial was stopped early after including nine participants, without providing any reasons and without publishing outcomes (<a href="./references#CD010615-bbs2-0004" title="NCT01301963. Filgrastim with or without plerixafor in treating patients with multiple myeloma previously treated with lenalidomide. https://clinicaltrials.gov/ct2/show/record/NCT01301963 (accessed 30 November 2014). ">NCT01301963</a>). The study investigator did not respond to email. Another trial was reported as being completed in 2009, but no details have been published (<a href="./references#CD010615-bbs2-0003" title="NCT00665314. Evaluation of the safety and efficacy of the addition of AMD3100 to a G‐CSF mobilization regimen in patients with lymphoma (NHL and HD) and multiple myeloma (MM). https://clinicaltrials.gov/ct2/show/NCT00665314 (accessed 30 November 2014). ">NCT00665314</a>). We contacted the study investigator via email, but he was not able to provide the missing data. The study flow diagram in <a href="#CD010615-fig-0001">Figure 1</a> provides an overview of the searching process. </p> <div class="figure" id="CD010615-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010615-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010615-sec-0054"> <h4 class="title">Included studies</h4> <p>One trial included people with MM (<a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>), whereas the second trial analysed the effect of plerixafor on people with NHL (<a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a>). The third trial evaluated people with MM with at least two cycles of lenalidomide from July 2011 to June 2013 and included nine participants (<a href="./references#CD010615-bbs2-0004" title="NCT01301963. Filgrastim with or without plerixafor in treating patients with multiple myeloma previously treated with lenalidomide. https://clinicaltrials.gov/ct2/show/record/NCT01301963 (accessed 30 November 2014). ">NCT01301963</a>). The fourth trial evaluated the safety and efficacy of the addition of plerixafor to a G‐CSF mobilisation regimen in people with lymphoma (NHL and HL) and MM (<a href="./references#CD010615-bbs2-0003" title="NCT00665314. Evaluation of the safety and efficacy of the addition of AMD3100 to a G‐CSF mobilization regimen in patients with lymphoma (NHL and HD) and multiple myeloma (MM). https://clinicaltrials.gov/ct2/show/NCT00665314 (accessed 30 November 2014). ">NCT00665314</a>); the study period lasted from November 2007 to June 2009 with an enrolment of five participants. The third and fourth trial did not provide any outcome, even after we had contacted the study investigators via email. Therefore we have only described them further in the <a href="./references#CD010615-sec-0102" title="">Characteristics of included studies</a> section. </p> <section id="CD010615-sec-0055"> <h5 class="title">Design</h5> <p><a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> and <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a> were multicentre, randomised (1:1), double‐blind, placebo‐controlled studies. </p> </section> <section id="CD010615-sec-0056"> <h5 class="title">Sample sizes</h5> <p><a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a> randomised 302 participants; 148 entered the plerixafor arm and 154 the placebo arm. <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> allocated 150 participants to the plerixafor arm and 148 to the placebo arm. </p> </section> <section id="CD010615-sec-0057"> <h5 class="title">Locations</h5> <p>The participants in <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a> were treated at 38 sites in the USA, one site in Canada, and one site in Germany. <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> was conducted at 32 sites, but detailed information on the countries was not provided. </p> </section> <section id="CD010615-sec-0058"> <h5 class="title">Participants</h5> <p>In <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>, participants had a median age of 58.2 (± 8.4) in the plerixafor arm and 58.4 (± 8.6) in the placebo arm. The amount of male participants was 67.6% in the plerixafor arm and 69.5% in the placebo arm. In the plerixafor arm, 61.5% of participants had a MM at stage III at initial diagnosis. In the placebo arm, 58.4% of participants were at stage III. </p> <p>In <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a>, the median age of the participants in the plerixafor arm was 56 years (29 to 75) with 66.7% male participants. In the placebo group, the median age was 59 years (22 to 75) with 68.9% male participants. In the plerixafor arm, 34.0% of the participants had a first complete remission, 20.0% a second complete remission, 17.3% a first partial remission, and 28.7% a second partial remission. In the placebo arm, 29.7% of the participants had a first complete remission, 19.6% a second complete remission, 12.8% a first partial remission, and 36.5% a second partial remission. The current remission status of two placebo participants was unknown. </p> </section> <section id="CD010615-sec-0059"> <h5 class="title">Interventions</h5> <p>In both trials the participants received G‐CSF, 10 μg/kg subcutaneously daily in the mornings for up to eight days. In the evening of day four, participants in both trials received plerixafor, 240 μg/kg or placebo subcutaneously for up to four days. The apheresis began at day five in both trials. In <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>, apheresis continued daily for up to four days or until more than or equal to 6 x 10<sup>6</sup> CD34+ cells/kg were collected. In <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a>, apheresis continued daily for up to four days or until more than or equal to 5 x 10<sup>6</sup> CD34+ cells/kg were collected. </p> </section> <section id="CD010615-sec-0060"> <h5 class="title">Outcomes</h5> <p>Both trials analysed overall survival throughout a 12 months' follow‐up. The studies defined different endpoints to analyse successful stem cell collection and the proportion of participants achieving the optimal CD34+ cell target for transplantation. Both trials also examined the number of days to successful neutrophil and platelet engraftment, as well as adverse events. Neither study evaluated quality of life. </p> </section> <section id="CD010615-sec-0061"> <h5 class="title">Conflict of interest</h5> <p>Both trials were supported and sponsored by the Genzyme Corporation.</p> </section> </section> <section id="CD010615-sec-0062"> <h4 class="title">Excluded studies</h4> <p>After a detailed evaluation of the selected full‐text publications, we excluded four studies, of which two were post‐hoc retrospective analyses (<a href="./references#CD010615-bbs2-0006" title="MaziarzRT , MicallefIN , StiffP , BolwellBJ , MarulkarS , CalandraGC , et al. Plerixafor plus G‐CSF is an effective regimen to mobilize hematopoietic stem cells in NHL patients with circulating peripheral blood CD34+ cells/{micro}l &lt; 10. Blood2009;114:33. MaziarzRT , NademaneeAP , MicallefIN , StiffPJ , CalandraG , AngellJ , et al. Plerixafor plus granulocyte colony‐stimulating factor improves the mobilization of hematopoietic stem cells in patients with non‐Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biology of Blood and Marrow Transplantation2013;19:670‐5. ">Maziarz 2013</a>; <a href="./references#CD010615-bbs2-0008" title="StiffPJ , MicallefI , NademaneeAP , StadtmauerEA , MaziarzRT , BolwellBJ , et al. Transplanted CD34(+) cell dose is associated with long‐term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non‐Hodgkin lymphoma or multiple myeloma. Biology of Blood and Marrow Transplantation2011:1146‐53. ">Stiff 2011</a>), one was a non‐randomised open‐label rescue protocol (<a href="./references#CD010615-bbs2-0007" title="MicallefIN , StiffPJ , DiPersioJF , MaziarzRT , McCartyJM , AngellJ , et al. Successful stem cell mobilization rescue by AMD3100 (Plerixafor) + G‐CSF for patients who failed primary mobilization: Results from the phase III (3101‐NHL) study. Blood (ASH Annu Meet Abstr)2007;110(11):602. MicallefIN , StiffPJ , DiPersioJF , MaziarzRT , McCartyJM , BridgerG , et al. Successful stem cell remobilization using plerixafor (Mozobil) plus granulocyte colony‐stimulating factor in patients with non‐Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biology of Blood and Marrow Transplantation2009:1578‐86. ">Micallef 2009</a>), and in one trial the study design was amended during the treatment period (<a href="./references#CD010615-bbs2-0005" title="FlomenbergN , DevineSM , DiPersioJF , LiesveldJL , McCartyJM , RowleySD , et al. The use of AMD3100 plus G‐CSF for autologous hematopoietic progenitor cell mobilization is superior to G‐CSF alone. Blood2005;106(5):1867‐74. ">Flomenberg 2005</a>). For more details, see <a href="./references#CD010615-sec-0103" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD010615-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>There was low risk of bias in <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> and <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>; however, in <a href="./references#CD010615-bbs2-0004" title="NCT01301963. Filgrastim with or without plerixafor in treating patients with multiple myeloma previously treated with lenalidomide. https://clinicaltrials.gov/ct2/show/record/NCT01301963 (accessed 30 November 2014). ">NCT01301963</a> and <a href="./references#CD010615-bbs2-0003" title="NCT00665314. Evaluation of the safety and efficacy of the addition of AMD3100 to a G‐CSF mobilization regimen in patients with lymphoma (NHL and HD) and multiple myeloma (MM). https://clinicaltrials.gov/ct2/show/NCT00665314 (accessed 30 November 2014). ">NCT00665314</a> we considered the potential risk of bias as high since neither study has published outcomes nor reported reasons for stopping early. For detailed information, see the 'Risk of bias' table in <a href="./references#CD010615-sec-0102" title="">Characteristics of included studies</a>, <a href="#CD010615-fig-0002">Figure 2</a>, and <a href="#CD010615-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010615-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010615-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010615-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010615-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010615-sec-0064"> <h4 class="title">Allocation</h4> <p>We judged random sequence generation as 'low risk' for all four trials because participants were randomly assigned. In <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>, randomisation was stratified by study centre, baseline platelet count, and type of transplantation planned. No information was available for allocation concealment for <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a>, <a href="./references#CD010615-bbs2-0004" title="NCT01301963. Filgrastim with or without plerixafor in treating patients with multiple myeloma previously treated with lenalidomide. https://clinicaltrials.gov/ct2/show/record/NCT01301963 (accessed 30 November 2014). ">NCT01301963</a>, and <a href="./references#CD010615-bbs2-0003" title="NCT00665314. Evaluation of the safety and efficacy of the addition of AMD3100 to a G‐CSF mobilization regimen in patients with lymphoma (NHL and HD) and multiple myeloma (MM). https://clinicaltrials.gov/ct2/show/NCT00665314 (accessed 30 November 2014). ">NCT00665314</a>. </p> </section> <section id="CD010615-sec-0065"> <h4 class="title">Blinding</h4> <p><a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> and <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a> were double‐blind, placebo‐controlled studies, therefore we rated performance and detection bias as 'low risk'. <a href="./references#CD010615-bbs2-0004" title="NCT01301963. Filgrastim with or without plerixafor in treating patients with multiple myeloma previously treated with lenalidomide. https://clinicaltrials.gov/ct2/show/record/NCT01301963 (accessed 30 November 2014). ">NCT01301963</a> was an open‐label study, and in <a href="./references#CD010615-bbs2-0003" title="NCT00665314. Evaluation of the safety and efficacy of the addition of AMD3100 to a G‐CSF mobilization regimen in patients with lymphoma (NHL and HD) and multiple myeloma (MM). https://clinicaltrials.gov/ct2/show/NCT00665314 (accessed 30 November 2014). ">NCT00665314</a> only participants were blinded, therefore we rated performance and detection bias as 'high risk' for both trials. </p> </section> <section id="CD010615-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>We judged attrition bias as 'low risk' for <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> and <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a> because all participants who withdrew from the studies or entered rescue procedure were documented in detail in the patients' flow charts. We rated attrition bias as 'high risk' for <a href="./references#CD010615-bbs2-0003" title="NCT00665314. Evaluation of the safety and efficacy of the addition of AMD3100 to a G‐CSF mobilization regimen in patients with lymphoma (NHL and HD) and multiple myeloma (MM). https://clinicaltrials.gov/ct2/show/NCT00665314 (accessed 30 November 2014). ">NCT00665314</a>, as the study investigator could not provide the missing data, and as 'unclear risk' for <a href="./references#CD010615-bbs2-0004" title="NCT01301963. Filgrastim with or without plerixafor in treating patients with multiple myeloma previously treated with lenalidomide. https://clinicaltrials.gov/ct2/show/record/NCT01301963 (accessed 30 November 2014). ">NCT01301963</a>, as the study investigator did not respond to email. </p> </section> <section id="CD010615-sec-0067"> <h4 class="title">Selective reporting</h4> <p>The study protocols were available and all outcomes were reported in detail for <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> and <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a> (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); therefore we judged reporting bias as 'low risk'. We rated reporting bias as 'high risk' for <a href="./references#CD010615-bbs2-0003" title="NCT00665314. Evaluation of the safety and efficacy of the addition of AMD3100 to a G‐CSF mobilization regimen in patients with lymphoma (NHL and HD) and multiple myeloma (MM). https://clinicaltrials.gov/ct2/show/NCT00665314 (accessed 30 November 2014). ">NCT00665314</a>, as the study investigator could not provide the missing data, and as 'unclear risk' for <a href="./references#CD010615-bbs2-0004" title="NCT01301963. Filgrastim with or without plerixafor in treating patients with multiple myeloma previously treated with lenalidomide. https://clinicaltrials.gov/ct2/show/record/NCT01301963 (accessed 30 November 2014). ">NCT01301963</a>, as the study investigator did not respond to email. </p> </section> <section id="CD010615-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> and <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a> were supported by the Genzyme Corporation, the manufacturer of plerixafor. We therefore rated the risk of other bias as 'unclear'. We rated other bias as 'high risk' for <a href="./references#CD010615-bbs2-0003" title="NCT00665314. Evaluation of the safety and efficacy of the addition of AMD3100 to a G‐CSF mobilization regimen in patients with lymphoma (NHL and HD) and multiple myeloma (MM). https://clinicaltrials.gov/ct2/show/NCT00665314 (accessed 30 November 2014). ">NCT00665314</a>, as the study investigator could not provide the missing data, and as 'unclear risk' for <a href="./references#CD010615-bbs2-0004" title="NCT01301963. Filgrastim with or without plerixafor in treating patients with multiple myeloma previously treated with lenalidomide. https://clinicaltrials.gov/ct2/show/record/NCT01301963 (accessed 30 November 2014). ">NCT01301963</a>, as the study investigator did not respond to email. </p> </section> </section> <section id="CD010615-sec-0069"> <h3 class="title" id="CD010615-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD010615-tbl-0001"><b>Summary of findings for the main comparison</b> Plerixafor versus placebo for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma</a> </p> <p>The trial <a href="./references#CD010615-bbs2-0004" title="NCT01301963. Filgrastim with or without plerixafor in treating patients with multiple myeloma previously treated with lenalidomide. https://clinicaltrials.gov/ct2/show/record/NCT01301963 (accessed 30 November 2014). ">NCT01301963</a> was prematurely closed and no analysis was being done on collected data. Nine participants were randomised in this trial. The trial <a href="./references#CD010615-bbs2-0003" title="NCT00665314. Evaluation of the safety and efficacy of the addition of AMD3100 to a G‐CSF mobilization regimen in patients with lymphoma (NHL and HD) and multiple myeloma (MM). https://clinicaltrials.gov/ct2/show/NCT00665314 (accessed 30 November 2014). ">NCT00665314</a>, which had an enrolment of five participants, was completed in 2009 and also did not report any results. </p> <section id="CD010615-sec-0070"> <h4 class="title">Primary outcomes</h4> <section id="CD010615-sec-0071"> <h5 class="title">Overall survival</h5> <p>No hazard ratios for overall survival were reported, therefore we analysed mortality at 12 months for the 600 included participants. The meta‐analysis did not show a statistically significant difference between participants treated with G‐CSF plus plerixafor and G‐CSF plus placebo (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.59 to 1.69; P = 1.00). For more details, see <a href="./references#CD010615-fig-0004" title="">Analysis 1.1</a>. </p> </section> <section id="CD010615-sec-0072"> <h5 class="title">Successful stem cell collection</h5> <p>In <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>, the primary endpoint was the proportion of participants collecting more than or equal to 6 x 10<sup>6</sup> CD34+ cells/kg in two or fewer apheresis days. In <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a>, the primary endpoint was the percentage of participants who collected more than or equal to 5 x 10<sup>6</sup> CD34+ cells/kg in four or fewer apheresis days. The meta‐analysis showed a significant advantage for those participants randomised to plerixafor (RR 2.42, 95% CI 1.98 to 2.96; P &lt; 0.00001), with important heterogeneity (I<sup>2</sup> = 67%). Reasons for the heterogeneity could be different underlying condition or different targeted stem cell number. For detailed information, see <a href="./references#CD010615-fig-0005" title="">Analysis 1.2</a>. </p> <p>Furthermore, in both trials the time required to reach the primary endpoint was significantly shorter in the plerixafor group (<a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>: P &lt; 0.001; <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a>: P &lt; 0.0001). </p> </section> </section> <section id="CD010615-sec-0073"> <h4 class="title">Secondary outcomes</h4> <section id="CD010615-sec-0074"> <h5 class="title">Progression‐free survival</h5> <p>Not reported.</p> </section> <section id="CD010615-sec-0075"> <h5 class="title">Proportion of participants achieving the optimal CD34+ cell target for transplantation</h5> <p>In <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>, 95.3% of 148 participants in the plerixafor arm and 88.3% in the placebo arm achieved the secondary endpoint, which was defined as the number of participants collecting more than or equal to 2 x 10<sup>6</sup> CD34+ cells/kg in two or fewer apheresis days (RR 1.08, 95% CI 1.01 to 1.15). </p> <p>In <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a>, statistically significantly more participants in the plerixafor group (86.7%) compared to the control arm (47.3%) met this endpoint (RR 1.83, 95% CI 1.53 to 2.20). </p> <p>Due to the high heterogeneity between the trials, we did not pool these data. For more details, see <a href="./references#CD010615-fig-0006" title="">Analysis 1.3</a>. </p> </section> <section id="CD010615-sec-0076"> <h5 class="title">Time to engraftment in transplanted participants</h5> <p>Time to engraftment could be measured only for those participants that were transplanted. As there was high heterogeneity between studies, we did not meta‐analyse these data for transplantation. In addition, as only the median time to engraftment was reported, without the publishing of standard error or standard deviation, we could not meta‐analyse the data for engraftment. </p> </section> <section id="CD010615-sec-0077"> <h5 class="title">Number of transplanted patients</h5> <p>In <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>, 142 participants (95.9%) in the plerixafor arm and 136 (88.3%) in the placebo arm underwent transplantation (RR 1.09, 95% CI 1.02 to 1.16). Median time to engraftment was 11 days for neutrophils and 18 days for platelets in both groups. One participant in the plerixafor arm and one participant in the control arm died 10 and 13 days after transplantation, respectively. Nevertheless, using clinical and laboratory data we identified no graft failures. </p> <p>In <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a>, 135 participants (90%) in the plerixafor group and 82 (55.4%) in the control group underwent transplantation (RR 1.62, 95% CI 1.39 to 1.89). The median time was 10 days for neutrophil engraftment and 20 days for platelet engraftment in each arm. All participants in both groups who underwent transplantation had successful neutrophil engraftment. For platelet engraftment, the study reported two graft failures in the plerixafor arm but none in the placebo arm. </p> <p>For more details, see <a href="./references#CD010615-fig-0007" title="">Analysis 1.4</a>. </p> </section> <section id="CD010615-sec-0078"> <h5 class="title">Quality of life</h5> <p>Not reported.</p> </section> <section id="CD010615-sec-0079"> <h5 class="title">Adverse events</h5> <p>For the period from participants' randomisation to the day before high‐dose chemotherapy (period one), the meta‐analysis did not show a statistically significant difference between the plerixafor and placebo group in terms of adverse events (RR 1.02, 95% CI 0.99 to 1.06; P = 0.19). </p> <p>Only <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> reported serious adverse events in period one. Eight serious adverse events occurred in the plerixafor arm and 10 in the placebo arm (RR 0.77, 95% CI 0.31 to 1.90; P = 0.58). </p> <p>The meta‐analysis of adverse events that led to discontinuation of study treatment did not show a statistically significant difference between the plerixafor and control group (RR 0.79, 95% CI 0.21 to 2.91; P = 0.72). </p> <p>Adverse events leading to study withdrawal also did not show a statistically significant result (RR 1.17, 95% CI 0.38 to 3.58; P = 0.78). </p> <p>For detailed information, see <a href="./references#CD010615-fig-0008" title="">Analysis 1.5</a>, <a href="./references#CD010615-fig-0009" title="">Analysis 1.6</a>, <a href="./references#CD010615-fig-0010" title="">Analysis 1.7</a>, and <a href="./references#CD010615-fig-0011" title="">Analysis 1.8</a>. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010615-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010615-sec-0080"></div> <section id="CD010615-sec-0081"> <h3 class="title" id="CD010615-sec-0081">Summary of main results</h3> <p> <ul id="CD010615-list-0010"> <li> <p>As no hazard ratios for overall survival were provided, we analysed mortality at 12 months. No evidence for differences between plerixafor and control arm regarding mortality emerged in the meta‐analysis. </p> </li> <li> <p>The meta‐analysis of adverse events in study period one (stem cell mobilisation) did not show a statistically significant difference between the plerixafor and placebo group. </p> </li> <li> <p>Regarding the primary endpoint of successful stem cell collection, the meta‐analysis showed a significant advantage for those participants randomised to plerixafor, with important heterogeneity. Reasons for the heterogeneity could be different underlying condition or different targeted stem cell number. In <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>, the primary endpoint was defined as the proportion of participants collecting more than or equal to 6 x 10<sup>6</sup> CD34+ cells/kg in two or fewer apheresis days. In <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a>, the primary endpoint was the percentage of participants who collected more than or equal to 5 x 10<sup>6</sup> CD34+ cells/kg in four or fewer apheresis days. It is common practice to define a higher primary endpoint of collected stem cells for MM patients, as they often need a second transplantation. In both studies, the time to reach the primary endpoint was significantly shorter in the plerixafor group compared to the control group. </p> </li> <li> <p>In <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>, 95.9% of participants in the plerixafor arm and 88.3% in the placebo arm underwent transplantation. By contrast, in <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a>, 90% of participants in the plerixafor group but only 55.4% in the control group underwent transplantation. </p> </li> <li> <p>In both trials, there was no evidence for a difference between participants in the plerixafor and the control group in terms of time to neutrophil and platelet engraftment. </p> </li> <li> <p>None of the trials reported quality‐of‐life events or progression‐free survival.</p> </li> </ul> </p> </section> <section id="CD010615-sec-0082"> <h3 class="title" id="CD010615-sec-0082">Overall completeness and applicability of evidence</h3> <p>The following aspects should be considered when interpreting the results of this meta‐analysis.</p> <p> <ul id="CD010615-list-0011"> <li> <p>Trial <a href="./references#CD010615-bbs2-0004" title="NCT01301963. Filgrastim with or without plerixafor in treating patients with multiple myeloma previously treated with lenalidomide. https://clinicaltrials.gov/ct2/show/record/NCT01301963 (accessed 30 November 2014). ">NCT01301963</a>, terminated in June 2013, did not analyse and publish collected data due to low enrolment (nine participants). The study investigator did not respond to email. Study <a href="./references#CD010615-bbs2-0003" title="NCT00665314. Evaluation of the safety and efficacy of the addition of AMD3100 to a G‐CSF mobilization regimen in patients with lymphoma (NHL and HD) and multiple myeloma (MM). https://clinicaltrials.gov/ct2/show/NCT00665314 (accessed 30 November 2014). ">NCT00665314</a>, completed in June 2009 with randomisation of five participants, did not report any outcomes. Genzyme, the responsible party, was not able to provide the missing data. </p> </li> <li> <p>Trial <a href="./references#CD010615-bbs2-0011" title="NCT01767714. Evaluation of Plerixafor Plus G‐CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non‐Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation. https://www.clinicaltrials.gov/ct2/show/NCT01767714?term=NCT01767714&amp;rank=1 (accessed 30 May 2015). ">NCT01767714</a> (classified as an ongoing study), completed in November 2014 with enrolment of 100 participants, has not to this date reported any outcomes, however the trial could publish results in the near future, which may affect the results of this review. The collaborator of the study, Genzyme, did not respond to email. </p> </li> <li> <p>The two analysed studies, <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> and <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>, have been published several times. </p> </li> <li> <p>Besides mortality at 12 months, number of collected stem cells, and adverse events, the studies did not provide much clinical data (e.g. quality of life). </p> </li> <li> <p>Both trials were conducted by the same study director and were supported by the Genzyme Corporation, the manufacturer of plerixafor. </p> </li> </ul> </p> </section> <section id="CD010615-sec-0083"> <h3 class="title" id="CD010615-sec-0083">Quality of the evidence</h3> <p>The risk of bias in <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> and <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a> was low as they were randomised, double‐blind, placebo‐controlled studies. We rated the risk of performance, detection, attrition, and reporting bias as low for both trials. The quality of allocation concealment (selection bias) in <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> remained unclear as the publication provided no information. We judged the risk of selection bias in <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a> as low. Due to the sponsorship of the Genzyme Corporation, we rated the risk of other bias as unclear for both trials. </p> <p>We could conduct a meta‐analysis for mortality at 12 months, successful stem cell collection, and adverse events. We rated the quality of the evidence for mortality after one year as moderate due to the wide confidence interval and imprecision. We judged the quality of evidence for successful stem cell collection and adverse events during study period one (stem cell mobilisation) as high. </p> <p>There was a low risk of publication bias, but we did not downgrade the quality of evidence because although two trials, which were terminated early, did not report results, they were stopped early due to low recruitment, and included 14 participants only. We therefore judged potential risk of publication bias as low. The first of these two trials, <a href="./references#CD010615-bbs2-0004" title="NCT01301963. Filgrastim with or without plerixafor in treating patients with multiple myeloma previously treated with lenalidomide. https://clinicaltrials.gov/ct2/show/record/NCT01301963 (accessed 30 November 2014). ">NCT01301963</a>, was conducted and sponsored by the Case Comprehensive Cancer Center in Ohio, USA and was terminated in 2013. On clinicaltrials.gov (<a href="https://clinicaltrials.gov/ct2/show/results/NCT01301963?sect=X01256#all" target="_blank">https://clinicaltrials.gov/ct2/show/results/NCT01301963?sect=X01256#all</a>), the investigators stated that they had recruited nine participants, but due to low enrolment (10% of anticipated participants), they were doing no analysis on data collected in this study. We contacted principal investigator Hien Duong, MD, to obtain the collected data, but he did not respond. The second trial <a href="./references#CD010615-bbs2-0003" title="NCT00665314. Evaluation of the safety and efficacy of the addition of AMD3100 to a G‐CSF mobilization regimen in patients with lymphoma (NHL and HD) and multiple myeloma (MM). https://clinicaltrials.gov/ct2/show/NCT00665314 (accessed 30 November 2014). ">NCT00665314</a> was terminated in 2009; study sponsor and collaborator Genzyme stated via email that the low enrolment (five participants) was probably due to the compassionate use programme for plerixafor that had started at the same time. Genzyme was not able to provide more information on the outcomes. </p> </section> <section id="CD010615-sec-0084"> <h3 class="title" id="CD010615-sec-0084">Potential biases in the review process</h3> <p>We tried to avoid bias by performing all relevant processes in duplicate. We are not aware of any obvious deficiencies in our review process. However, the small number of trials included in this analysis could lead to publication bias, as we could not generate a funnel plot. As stated above, there is a low risk of publication bias, because of three studies that were completed and have not yet published results. </p> </section> <section id="CD010615-sec-0085"> <h3 class="title" id="CD010615-sec-0085">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD010615-bbs2-0048" title="SheppardD , BredesonC , AllanD , TayJ . Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biology of Blood and Marrow Transplantation2012;18(8):1191‐203. [PUBMED: 22261379] ">Sheppard 2012</a> conducted a systematic review of RCTs of haematopoietic stem cell mobilisation strategies for autologous transplantation for haematologic malignancies. They analysed 28 articles including <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> and <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a> as well as studies with chemotherapy mobilisation strategies. Due to the different methodological quality of the trials, they were not able to compare the studies via meta‐analysis and draw definitive conclusions. Regarding <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> and <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>, <a href="./references#CD010615-bbs2-0048" title="SheppardD , BredesonC , AllanD , TayJ . Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biology of Blood and Marrow Transplantation2012;18(8):1191‐203. [PUBMED: 22261379] ">Sheppard 2012</a> stated that primary mobilisation failure in the control groups could be a result of a too‐low G‐CSF dose. <a href="./references#CD010615-bbs2-0048" title="SheppardD , BredesonC , AllanD , TayJ . Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biology of Blood and Marrow Transplantation2012;18(8):1191‐203. [PUBMED: 22261379] ">Sheppard 2012</a> recommended a risk‐adapted, cost‐effective approach for the use of plerixafor. <a href="./references#CD010615-bbs2-0020" title="DuongHK , BolwellBJ , RybickiL , KooA , HsiED , FigueroaP , et al. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield. Journal of Clinical Apheresis2011;26(3):111‐5. [PUBMED: 21647951] ">Duong 2011</a> and <a href="./references#CD010615-bbs2-0014" title="AbhyankarS , DejarnetteS , AljitawiO , GangulyS , MerkelD , McGuirkJ . A risk‐based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplantation2012;47(4):483‐7. [PUBMED: 21725372] ">Abhyankar 2012</a> described a risk‐based algorithm for the use of plerixafor based on analysing the CD34+ cell count on the first day of collection. <a href="./references#CD010615-bbs2-0020" title="DuongHK , BolwellBJ , RybickiL , KooA , HsiED , FigueroaP , et al. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield. Journal of Clinical Apheresis2011;26(3):111‐5. [PUBMED: 21647951] ">Duong 2011</a> identified participants with a day one CD34+ cell yield of &lt;= 0.7 x 10<sup>6</sup> CD34+ cells/kg as being at risk for mobilisation failure. <a href="./references#CD010615-bbs2-0018" title="CostaLJ , MillerAN , AlexanderET , HoganKR , ShabbirM , SchaubC , et al. Growth factor and patient‐adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplantation2011;46(4):523‐8. [PUBMED: 20622909] ">Costa 2011</a> described a cost‐based algorithm to decide whether to add plerixafor on the basis of the CD34+ cell count on the fourth day of G‐CSF application. </p> <p><a href="./references#CD010615-bbs2-0022" title="GiraltS , CostaL , SchriberJ , DiPersioJ , MaziarzR , McCartyJ , et al. Optimizing autologous stem cell mobilization strategies to improve patient outcome: consensus guidelines and recommendations. Biology of Blood and Marrow Transplantation2014;20(3):295‐308. [PUBMED: 24141007] ">Giralt 2014</a> discussed recommendations for optimal stem cell mobilisation strategies. With reference to <a href="./references#CD010615-bbs2-0001" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood2007;110(11):601. DiPersioJF , MicallefIN , StiffPJ , BolwellBJ , MaziarzRT , JacobsenE , et al. Phase III prospective randomized double‐blind placebo‐controlled trial of plerixafor plus granulocyte colony‐stimulating factor compared with placebo plus granulocyte colony‐stimulating factor for autologous stem‐cell mobilization and transplantation for patients with non‐Hodgkin's lymphoma. Journal of Clinical Oncology2009;27:4767‐73. DiPersioJF , MicallefINM , StiffPJ , BolwellBJ , MaziarzRT , BridgerG , et al. Months report from the phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112:1136. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. ">AMD3100‐3101 NHL</a> and <a href="./references#CD010615-bbs2-0002" title="BolwellBJ , NademaneeAP , StiffP , StadtmauerE , MaziarzRT , MicallefIN , et al. Mobilization with plerixafor (Mozobil (R)) plus G‐CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G‐CSF: Results from two randomized placebo‐controlled trials in patients with multiple myeloma or non‐Hodgkin's lymphoma. Blood2009;114:3224. DiPersioJF , StadtmauerEA , NademaneeA , MicallefIN , StiffPJ , KaufmanJL , et al. Plerixafor and G‐CSF versus placebo and G‐CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720‐6. DiPersioJF , StadtmauerEA , NademaneeAP , MicallefINM , StiffPJ , BridgerG , et al. 12 months report from a phase 3 study of plerixafor + G‐CSF vs. placebo + G‐CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood2008;112:3312. DiPersioJF , StadtmauerEA , NademaneeAP , StiffPJ , MicallefIN , AngellJ , et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, comparative trial of AMD3100 (plerixafor) + G‐CSF vs. G‐CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]. Blood2007;110(11):137a‐8a. MicallefIN , StiffP , StadtmauerE , BolwellBJ , MarulkarS , HsuFJ , et al. Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G‐CSF versus placebo plus G‐CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front‐line or rescue mobilization. Blood2009;114:2319. NademaneeAP , DiPersioJF , MaziarzRT , StadtmauerEA , MicallefIN , StiffPJ , et al. Plerixafor plus granulocyte colony‐stimulating factor versus placebo plus granulocyte colony‐stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation2012;18:1564‐72. NademaneeAP , StadtmauerE , MicallefIN , StiffP , MarulkarS , CalandraGC , et al. Plerixafor (Mozobi (R)) plus G‐CSF is more effective than placebo plus G‐CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (&lt;20 cells/{micro}l) peripheral blood CD34+ cell count. Blood2009;114:3230. ">AMD3100‐3102 MM</a>, they agreed that plerixafor‐containing strategies reduce mobilisation failure rates. They recommend using plerixafor for remobilisation attempts or for predictable poor mobilisers. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010615-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/urn:x-wiley:14651858:media:CD010615:CD010615-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_t/tCD010615-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010615-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full#CD010615-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010615-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/urn:x-wiley:14651858:media:CD010615:CD010615-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_t/tCD010615-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010615-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full#CD010615-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010615-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/urn:x-wiley:14651858:media:CD010615:CD010615-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_t/tCD010615-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010615-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full#CD010615-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010615-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/urn:x-wiley:14651858:media:CD010615:CD010615-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_t/tCD010615-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plerixafor versus placebo, Outcome 1 Mortality at 12 months." data-id="CD010615-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Plerixafor versus placebo, Outcome 1 Mortality at 12 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/references#CD010615-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010615-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/urn:x-wiley:14651858:media:CD010615:CD010615-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_t/tCD010615-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plerixafor versus placebo, Outcome 2 Successful stem cell collection." data-id="CD010615-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Plerixafor versus placebo, Outcome 2 Successful stem cell collection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/references#CD010615-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010615-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/urn:x-wiley:14651858:media:CD010615:CD010615-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_t/tCD010615-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plerixafor versus placebo, Outcome 3 Proportion of participants achieving the optimal CD34+ cell target for transplantation." data-id="CD010615-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Plerixafor versus placebo, Outcome 3 Proportion of participants achieving the optimal CD34+ cell target for transplantation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/references#CD010615-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010615-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/urn:x-wiley:14651858:media:CD010615:CD010615-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_t/tCD010615-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plerixafor versus placebo, Outcome 4 Number of transplanted patients." data-id="CD010615-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Plerixafor versus placebo, Outcome 4 Number of transplanted patients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/references#CD010615-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010615-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/urn:x-wiley:14651858:media:CD010615:CD010615-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_t/tCD010615-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plerixafor versus placebo, Outcome 5 Adverse events (during study period 1)." data-id="CD010615-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Plerixafor versus placebo, Outcome 5 Adverse events (during study period 1). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/references#CD010615-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010615-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/urn:x-wiley:14651858:media:CD010615:CD010615-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_t/tCD010615-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plerixafor versus placebo, Outcome 6 Serious adverse events (during period 1)." data-id="CD010615-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Plerixafor versus placebo, Outcome 6 Serious adverse events (during period 1). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/references#CD010615-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010615-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/urn:x-wiley:14651858:media:CD010615:CD010615-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_t/tCD010615-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plerixafor versus placebo, Outcome 7 Adverse events leading to discontinuation of study treatment." data-id="CD010615-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Plerixafor versus placebo, Outcome 7 Adverse events leading to discontinuation of study treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/references#CD010615-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010615-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/urn:x-wiley:14651858:media:CD010615:CD010615-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_t/tCD010615-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plerixafor versus placebo, Outcome 8 Adverse events leading to study withdrawal." data-id="CD010615-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Plerixafor versus placebo, Outcome 8 Adverse events leading to study withdrawal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/references#CD010615-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/media/CDSR/CD010615/image_n/nCD010615-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010615-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Plerixafor versus placebo for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Plerixafor versus placebo for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma<br/> <b>Settings:</b> Hospital<br/> <b>Intervention:</b> Plerixafor versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Plerixafor</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality (12 months)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1</b> <br/> (0.59 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>600<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>moderate <sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>As overall survival has not been reported, we calculated mortality at 12 months</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> <br/> (49 to 140) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to engraftment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported with standard error or standard deviation, therefore no meta‐analysis possible </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of transplanted participants</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to high heterogeneity we did not pool the data</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Successful stem cell collection</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>654 per 1000</b> </p> <p>(535 to 799)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.42</b> </p> <p>(1.98 to 2.96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (during stem cell mobilisation and collection)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.02</b> <br/> (0.99 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>593<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>939 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>958 per 1000</b> <br/> (930 to 996) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to imprecision: wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Plerixafor versus placebo for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/full#CD010615-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010615-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Plerixafor versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.59, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Successful stem cell collection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [1.98, 2.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion of participants achieving the optimal CD34+ cell target for transplantation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of transplanted patients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events (during study period 1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.99, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious adverse events (during period 1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.31, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events leading to discontinuation of study treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.21, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events leading to study withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.38, 3.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Plerixafor versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010615.pub2/references#CD010615-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010615.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010615-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010615-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010615-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010615-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010615\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010615\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010615\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010615\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010615\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010615.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010615.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010615.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010615.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010615.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727616990"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010615.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727616994"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010615.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb0636f73936d',t:'MTc0MDcyNzYxNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 